1-20 of 625 results for subject:"Blood transfusion services"
Librarians' tools
- Search time
- 0.304 seconds
- Solr query time
- 0.004 seconds
- Search query
- subject:"Blood transfusion services"
- We searched for
- subject_t:"Blood transfusion services" OR subject_ses:90357
Type
House
Session
Year
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask His Majesty's Government whether they plan to invest in the deployment of innovative blood technologies where they may strengthen the resilience and preparedness of the UK's blood supply chains.
To ask His Majesty's Government whether they plan to invest in the deployment of innovative blood technologies where they may strengthen the resilience and preparedness of the UK's blood supply chains.
As blood services are a devolved matter, NHS Blood and Transplant (NHSBT) is responsible for the blood service in England alone. NHSBT is a critical national infrastructure-owning organisation, and the Department of Health and Social Care works closely with it to review the criticality and resilience of blood services. The Joint Blood Stocks Working Group also brings together the Department of Health and Social Care and NHSBT with NHS England, the National Blood Transfusion Committee, and the Ministry of Defence to strengthen planning and emergency preparedness.
In addition, NHSBT is taking forward work to strengthen the resilience of blood supplies both in business-as-usual operations and during critical incidents, including through its partnerships with Defence Medical Command and the Air Ambulance services. This includes exploring new approaches to transfusion in emergency settings, such as dried plasma, or to the transport of blood samples using drones. This work will support future care in challenging environments, both civilian and defence, and help expand the options to deliver blood services, where it is safe, practical, and operationally beneficial to do so.
To ask His Majesty's Government what plans they have to publish a national blood resilience strategy covering health, defence and civil contingencies.
To ask His Majesty's Government what plans they have to publish a national blood resilience strategy covering health, defence and civil contingencies.
As blood services are a devolved matter, NHS Blood and Transplant (NHSBT) is responsible for the blood service in England alone. NHSBT is a critical national infrastructure-owning organisation, and the Department of Health and Social Care works closely with it to review the criticality and resilience of blood services. The Joint Blood Stocks Working Group also brings together the Department of Health and Social Care and NHSBT with NHS England, the National Blood Transfusion Committee, and the Ministry of Defence to strengthen planning and emergency preparedness.
In addition, NHSBT is taking forward work to strengthen the resilience of blood supplies both in business-as-usual operations and during critical incidents, including through its partnerships with Defence Medical Command and the Air Ambulance services. This includes exploring new approaches to transfusion in emergency settings, such as dried plasma, or to the transport of blood samples using drones. This work will support future care in challenging environments, both civilian and defence, and help expand the options to deliver blood services, where it is safe, practical, and operationally beneficial to do so.
To ask His Majesty's Government what joint work is being undertaken between the Ministry of Defence, the Department of Health and Social Care, and NHS bodies to assess and strengthen the resilience of the UK's blood supply in support of national defence planning.
To ask His Majesty's Government what joint work is being undertaken between the Ministry of Defence, the Department of Health and Social Care, and NHS bodies to assess and strengthen the resilience of the UK's blood supply in support of national defence planning.
Defence Medical Command (DMedC) has completed a detailed assessment of the requirement for blood to support military operations across a range of scenarios, including warfighting at scale. This work supports the ongoing strategic partnership with NHS Blood and Transplant (NHSBT) and the Department for Health and Social Care (DHSC) to assess and strengthen the resilience of the UK's blood supply in support of national defence planning. Further, the UK is leading work within NATO to improve how blood and blood products are collected, stored, and shared among NATO allies.
DMedC and NHSBT have signed a strategic partnership which will help innovate battlefield transfusion in an era of drone warfare. The joint research will drive research, improve urgent transfusion care in complex environments, and have dual use capability, which improve both military and civilian healthcare. This partnership underpins our commitment to providing the very best medical support to our people, wherever they serve.
The Defence Investment Plan has set out £20 million investment in battlefield blood products with £10 million for dried blood products, supporting the Blood Far Forward programme which enables life-saving blood transfusion care closer to the battlefield by reducing reliance on refrigeration, and £10 million for Tranexamic Acid (TXA) autoinjectors, which allows blood-clotting medication to be administered rapidly on the battlefield improving survival from severe blood loss.
To ask His Majesty's Government what assessment they have made of the resilience of the UK's blood supply to support military operations during a prolonged conflict or major national emergency.
To ask His Majesty's Government what assessment they have made of the resilience of the UK's blood supply to support military operations during a prolonged conflict or major national emergency.
Defence Medical Command (DMedC) has completed a detailed assessment of the requirement for blood to support military operations across a range of scenarios, including warfighting at scale. This work supports the ongoing strategic partnership with NHS Blood and Transplant (NHSBT) and the Department for Health and Social Care (DHSC) to assess and strengthen the resilience of the UK's blood supply in support of national defence planning. Further, the UK is leading work within NATO to improve how blood and blood products are collected, stored, and shared among NATO allies.
DMedC and NHSBT have signed a strategic partnership which will help innovate battlefield transfusion in an era of drone warfare. The joint research will drive research, improve urgent transfusion care in complex environments, and have dual use capability, which improve both military and civilian healthcare. This partnership underpins our commitment to providing the very best medical support to our people, wherever they serve.
The Defence Investment Plan has set out £20 million investment in battlefield blood products with £10 million for dried blood products, supporting the Blood Far Forward programme which enables life-saving blood transfusion care closer to the battlefield by reducing reliance on refrigeration, and £10 million for Tranexamic Acid (TXA) autoinjectors, which allows blood-clotting medication to be administered rapidly on the battlefield improving survival from severe blood loss.
Lords motion to consider. Agreed to on question.
Lords motion to consider. Agreed to on question.
My Lords, I am grateful for the opportunity to debate these regulations, which I think can fairly be described as routine. The Medicines and Healthcare products Regulatory Agency charges fees for most of its services and, to ensure continued cost recovery, updates its fees every two years. This regularity provides...
My Lords, I am grateful for the opportunity to debate these regulations, which I think can fairly be described as routine. The Medicines and Healthcare products Regulatory Agency charges fees for most of its services and, to ensure continued cost recovery, updates its fees every two years. This regularity provides...
My Lords, I thank the Minister for outlining the purpose of these regulations so eloquently and succinctly. It is clear that the change to the fee structure for regulating medical devices and medical products is part of a realm of profound importance both to public health and to the future...
My Lords, I thank the Minister for outlining the purpose of these regulations so eloquently and succinctly. It is clear that the change to the fee structure for regulating medical devices and medical products is part of a realm of profound importance both to public health and to the future...
My Lords, I also thank the Minister for introducing these regulations succinctly, as the noble Lord, Lord Scriven, said. Perhaps in common with the Liberal Democrats, we on these Benches—the numerous people on these Benches—do not seek to oppose this statutory instrument. Rather, we just wish to reflect on its...
My Lords, I also thank the Minister for introducing these regulations succinctly, as the noble Lord, Lord Scriven, said. Perhaps in common with the Liberal Democrats, we on these Benches—the numerous people on these Benches—do not seek to oppose this statutory instrument. Rather, we just wish to reflect on its...
I am most grateful to both noble Lords for their constructive contributions and their support for these measures. I welcome their questions and will do my best to respond to them.
I will first make a few general points that may assist. Noble Lords acknowledged the role of the MHRA, the...
I am most grateful to both noble Lords for their constructive contributions and their support for these measures. I welcome their questions and will do my best to respond to them.
I will first make a few general points that may assist. Noble Lords acknowledged the role of the MHRA, the...
Maybe I was not clear in my questioning. It is not about where it goes but this: if there is an automatic assumption that industry will cover the cost, what mechanisms are in place to make sure that there is efficiency, rather than a bloated approach where people think that,...
Maybe I was not clear in my questioning. It is not about where it goes but this: if there is an automatic assumption that industry will cover the cost, what mechanisms are in place to make sure that there is efficiency, rather than a bloated approach where people think that,...
That is understood. I am going to come on to that, because I think it is important. Of course, with any uplift in fee, I would expect that to be the case, but I have a particular response as I continue. The uplifts we are speaking about today ensure ongoing,...
That is understood. I am going to come on to that, because I think it is important. Of course, with any uplift in fee, I would expect that to be the case, but I have a particular response as I continue. The uplifts we are speaking about today ensure ongoing,...
If fees equal cost, I am not clear how calculations have been made that say that the NIC increases have not been put into that cost to be part of the fee increase, because it is a known cost. I am not clear why that suddenly becomes a potential cost...
If fees equal cost, I am not clear how calculations have been made that say that the NIC increases have not been put into that cost to be part of the fee increase, because it is a known cost. I am not clear why that suddenly becomes a potential cost...
I may not have been as clear as I would like to have been. I will try again. The national insurance contributions increase is an increased cost and that will have been factored into the new fees that are being put forward. The gentle challenge from the noble Lord, Lord...
I may not have been as clear as I would like to have been. I will try again. The national insurance contributions increase is an increased cost and that will have been factored into the new fees that are being put forward. The gentle challenge from the noble Lord, Lord...
Just for clarity, is the NIC cost known and has it been included in these fee increases? It is an important point. I do not want to push the Minister in terms of the actual figures, but I assume that the NIC figure is known and has been included in...
Just for clarity, is the NIC cost known and has it been included in these fee increases? It is an important point. I do not want to push the Minister in terms of the actual figures, but I assume that the NIC figure is known and has been included in...
I am just waiting for a bit of inspiration.
I am just waiting for a bit of inspiration.
Does the Minister want me to continue talking?
Does the Minister want me to continue talking?
Perhaps it would be best on this occasion if I review what the noble Lord has said and what I have said and write to him to clarify anything that is not quite clear.
In conclusion, I thank noble Lords for their contributions and for their support for the MHRA to...
Perhaps it would be best on this occasion if I review what the noble Lord has said and what I have said and write to him to clarify anything that is not quite clear.
In conclusion, I thank noble Lords for their contributions and for their support for the MHRA to...
Motion to consider. Agreed to on question.
Motion to consider. Agreed to on question.
To ask the Secretary of State for Health and Social Care, whether his Department plans to provide additional funding for domestic plasma collection; and if he will make an assessment of the potential impact of such funding on supply chains, in the context of the UK’s reliance on US plasma...
To ask the Secretary of State for Health and Social Care, whether his Department plans to provide additional funding for domestic plasma collection; and if he will make an assessment of the potential impact of such funding on supply chains, in the context of the UK’s reliance on US plasma...
The Department, NHS Blood and Transplant (NHSBT), and NHS England are working in partnership to develop a more sufficient and resilient supply of plasma, reducing the need for reliance on imports of plasma derived medicines.
A new end-to-end supply chain has been built, enabling the first National Health Service patients to receive life-saving plasma treatments made from the blood of United Kingdom donors in March, and increasing self-sufficiency for plasma derived medicines, specifically for immunoglobulins, from 0% to 25% self-sufficiency, and for albumin, from 0% to 80% self-sufficiency.
NHSBT has incorporated plasma collection into its business model, enabling growth in domestic plasma collection. This includes the use of modern automated collection technologies, used to enhance efficiency and consistency in the donation process. NHSBT is currently exploring future locations to expand its collection footprint and develop more donor centres.
Plasma collection is benefitting from the Department’s investment in NHSBT’s work to increase blood collection capacity and resilience, as plasma is collected from whole blood donations as well as dedicated plasma donation.